Dynamic programmed death-ligand 1 and multimodal biomarkers in gastric cancer immunotherapy
World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)
DOI: 10.4251/wjgo.120353 ↗Abstract
Immune checkpoint inhibitors targeting programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) are promising therapies for advanced gastric cancer (GC). However, challenges remain in identifying the best biomarkers to guide anti-PD-L1/PD-1 therapy. There are two competing paradigms for selecting immunotherapy biomarkers in clinical practice. One favors static biomarkers, such as Epstein-Barr virus positivity, microsatellite instability status, and the PD-L1 combined positive score, due to their track record in clinical trials. The other emerging view prefers dynamic tumor biomarkers, such as circulating tumor DNA, exosomal PD-L1, and immune cell profiling, to better reveal therapy-induced immune changes. This article discusses three main questions for real-time assessment of anti-PD-L1/PD-1 therapy in advanced GC: (1) What complementary approaches can overcome static PD-L1 assessment limitations; (2) How dynamic tumor biomarkers could be used in clinical practice to improve monitoring and patient selection; and (3) How multimodal artificial intelligence could support personalized immunotherapy. These strategies may improve patient selection and enhance the clinical impact of immunotherapy in advanced GC.
EUVIMED